Abstract
| Original language | English |
|---|---|
| Article number | 354 |
| Number of pages | 11 |
| Journal | Frontiers in Immunology |
| Volume | 3 |
| DOIs | |
| Publication status | Published - 27 Nov 2012 |
Cite this
}
Annexin A1 and the regulation of innate and adaptive immunity. / Gavins, Felicity N E; Hickey, Michael John.
In: Frontiers in Immunology, Vol. 3, 354, 27.11.2012.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Annexin A1 and the regulation of innate and adaptive immunity
AU - Gavins, Felicity N E
AU - Hickey, Michael John
PY - 2012/11/27
Y1 - 2012/11/27
N2 - Inflammation is the body s way of defending itself against noxious stimuli and pathogens. Under normal circumstances, the body is able to eliminate the insult and subsequently promote the resolution of inflammation and the repair of damaged tissues. The concept of homeostasis is one that not only requires a fine balance between both pro-inflammatory mediators and pro-resolving/anti-inflammatory mediators, but also that this balance occurs in a time and space-specific manner. This review examines annexin A1, an anti-inflammatory protein that, when used as an exogenous therapeutic, has been shown to be very effective in limiting inflammation in a diverse range of experimental models, including myocardial ischemia/reperfusion injury, arthritis, stroke, multiple sclerosis, and sepsis. Notably, this glucocorticoid-inducible protein, along with another anti-inflammatory mediator, lipoxin A(4), is starting to help explain and shape our understanding of the resolution phase of inflammation. In so doing, these molecules are carving the way for innovative drug discovery, based on the stimulation of endogenous pro-resolving pathways.
AB - Inflammation is the body s way of defending itself against noxious stimuli and pathogens. Under normal circumstances, the body is able to eliminate the insult and subsequently promote the resolution of inflammation and the repair of damaged tissues. The concept of homeostasis is one that not only requires a fine balance between both pro-inflammatory mediators and pro-resolving/anti-inflammatory mediators, but also that this balance occurs in a time and space-specific manner. This review examines annexin A1, an anti-inflammatory protein that, when used as an exogenous therapeutic, has been shown to be very effective in limiting inflammation in a diverse range of experimental models, including myocardial ischemia/reperfusion injury, arthritis, stroke, multiple sclerosis, and sepsis. Notably, this glucocorticoid-inducible protein, along with another anti-inflammatory mediator, lipoxin A(4), is starting to help explain and shape our understanding of the resolution phase of inflammation. In so doing, these molecules are carving the way for innovative drug discovery, based on the stimulation of endogenous pro-resolving pathways.
UR - http://www.ncbi.nlm.nih.gov/pubmed/23230437
U2 - 10.3389/fimmu.2012.00354
DO - 10.3389/fimmu.2012.00354
M3 - Article
VL - 3
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
M1 - 354
ER -